Cambridge Uni Scientists find potential new target for lung cancer therapy in CRUK funded research.

Cancer Research UK-funded scientists based at the University of Cambridge have identified a new target for the treatment of lung squamous cell carcinoma. Published in Nature Communications, their research found that lung squamous cell carcinoma (LUSC) cells contain high amounts of a protein called BCL11A, and that manipulating the gene responsible for this protein halted

Continue Reading

Bicycle and CRUK to launch first clinical trial of bicyclic peptide for use in treating tumours

Bicycle Therapeutics and Cancer Research UK have commenced the first clinical study to assess a bicyclic peptide to evaluate its potential in patients with advanced solid tumours. The first patient has now been dosed in a Phase I/IIa trial with BT1718, a first-in-class Bicycle Toxin Conjugate that targets Membrane Type 1 Matrix Metalloproteinase, which is

Continue Reading

CRUK and Institute of Cancer Research, London collaborate with Merck in new drug discovery alliance

Cancer Research UK’s Commercial Partnerships Team and The Institute of Cancer Research, announced a multi-project collaboration and licensing deal with Merck, a leading science and technology company, to discover and develop new anticancer drugs. “It is an exciting example of how successful academic networks and the scale of industry can combine to advance scientific and

Continue Reading